Read the Audiograph Booklet

Download the Audiograph Booklet in portable document format (PDF). To learn more about PDFs and Adobe Acrobat Reader, the program that reads them, please see our online media page.

Watch the Multimedia Presentation

The multimedia presentation is available online as a Macromedia Shockwave presentation. It also requires Apple Quicktime. To learn more about these free plugins, please see our online media page.

To begin, click an option below.
High Band (Cable, DSL, T1,T3, etc)
Low Band (28k, 56k, ISDN, etc)(28K and below are not recommended)
 

Topics included in the presentation are:

• Introduction
• Diagnosis and Epidemiology
• Acute Stress vs. PTSD
• Gender and PTSD
• Biology of PTSD
• Children and PTSD
• Treatment and Prevention
• Psychotherapy
• Medication Treatment
• Psychotherapy vs. Medication Treatment
• Noncompliance
• Conclusion

Take the Posttest

Download the CME Posttest and Registration/Evaluation Form in portable document format (PDF). To learn more about PDFs and Adobe Acrobat Reader, the program that reads them, please see our online media page.

CME Objectives

After completing this educational activity, participants should be able to:

• Discuss the epidemiology of posttraumatic stress disorder (PTSD)
• Describe the physiology of PTSD
• Select treatment options for patients suffering from trauma-related stress

Statement of Need and Purpose

Physicians responding to surveys in The Journal of Clinical Psychiatry and related CME activities have requested updated information on PTSD. This CME activity was designed to provide an updated review of the epidemiology, physiology, and treatment of PTSD. There are no prerequisites for this activity.

Accreditation Statement

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Credit Designation

Physicians Postgraduate Press, Inc. designates this educational activity for up to 2 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

Date of Original Release/Review

This Audiograph was published in February 2002. This activity is eligible for CME credit through February 28, 2003. The latest review of this material was November 2001.

Faculty

	Chair Mark H. Pollack, M.D. Massachusetts General Hospital, Boston
	Kathleen T. Brady, M.D., Ph.D. Medical University of South Carolina, Charleston
	Randall D. Marshall, M.D. New York State Psychiatric Institute, New York
	Rachel Yehuda, Ph.D. Bronx VA Medical Center, New York

Faculty Disclosure

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this continuing medical education activity were asked to complete a full disclosure statement. The information received is as follows:

Dr. Pollack has received honoraria from Bristol-Myers and Forest and has received honoraria and is a consultant for Lilly, Parke-Davis, Pfizer, SmithKline, Solvay, and Wyeth-Ayerst.

Dr. Brady has received research grant support and honoraria from and is a consultant and member of the speakers/advisory board for Pfizer, Abbott, Bristol-Myers, Parke-Davis, Lilly, and GlaxoSmithKline.

Dr. Marshall is a consultant for Wyeth-Ayerst; has received research grant support from GlaxoSmithKline; and has received honoraria from and is a member of the speakers/advisory board for Pfizer, GlaxoSmithKline, and Bristol-Myers.

Dr. Yehuda is a consultant for Novartis; has received research grant support from GlaxoSmithKline, Janssen, Wyeth-Ayerst, and Pfizer; has received honoraria from GlaxoSmithKline; and is a member of the speakers/advisory board for Pfizer, GlaxoSmithKline, Novartis, and Bristol-Myers.

Disclosure of Off-Label Usage

In this Audiograph, faculty may be presenting investigational information about pharmaceutical agents that is outside of U.S. Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications.

To the best of his knowledge, Dr. Pollack has determined that fluoxetine has not been approved by the U.S. Food and Drug Administration for the treatment of PTSD.

If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Acknowledgment

The material contained in this Audiograph was presented at the teleconference “Trauma and Stress: Diagnosis and Treatment,” held August 6, 2001.

The teleconference and this Audiograph were independently developed by the Physicians Postgraduate Press, Incorporated Office of Continuing Medical Education pursuant to an unrestricted educational grant from GlaxoSmithKline. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the publisher and CME provider or the commercial supporter.